Literature DB >> 8816917

Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules.

N S Ihrcke1, J L Platt.   

Abstract

Activation of endothelial cells by cytokines and endotoxin causes procoagulant and pro-inflammatory changes over a period of hours. We postulated that the same functional state might be achieved more rapidly by changes in the metabolism of heparan sulfate, which supports many of the normal functions of endothelial cells. We previously found that binding of anti-endothelial cell antibodies and activation of complement on endothelial cells causes the rapid shedding of endothelial cell heparan sulfate. Here we report the biochemical mechanism responsible for the release of the heparan sulfate. Stimulation of endothelial cells by anti-endothelial cell antibodies and complement resulted in the release of 35S-heparan sulfate proteoglycan and partially degraded 35S-heparan sulfate chains. Degradation of the 35S-heparan sulfate chains was not necessary for release since heparin and suramin prevented cleavage of the heparan sulfate but did not inhibit release from stimulated endothelial cells. The 35S-heparan sulfate proteoglycan released from endothelial cells originated from the cell surface and had a core protein similar in size (70.5 kD) to syndecan-1. Release was due to proteolytic cleavage of the protein core by serine and/or cysteine proteinases since the release of heparan sulfate was inhibited 87% by antipain and 53% by leupeptin. Release of heparan sulfate coincided with a decrease of approximately 7 kD in the mass of the protein core and with a loss of hydrophobicity of the proteoglycan, consistent with the loss of the hydrophobic transmembrane domain. The cleavage and release of cell-surface 35S-heparan sulfate proteoglycan might be a novel mechanism by which endothelial cells may rapidly acquire the functional properties of activated endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816917     DOI: 10.1002/(SICI)1097-4652(199609)168:3<625::AID-JCP15>3.0.CO;2-Y

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  27 in total

1.  Disaccharides generated from heparan sulphate or heparin modulate chemokine-induced T-cell adhesion to extracellular matrix.

Authors:  R Hershkoviz; H Schor; A Ariel; I Hecht; I R Cohen; O Lider; L Cahalon
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Characterization of potential CD138 negative myeloma "stem cells".

Authors:  Jacob H Christensen; Pia V Jensen; Ida B Kristensen; Niels Abildgaard; Marianne Lodahl; Thomas Rasmussen
Journal:  Haematologica       Date:  2012-06       Impact factor: 9.941

3.  Basic fibroblast growth factor does not prevent heparan sulphate proteoglycan catabolism in intact cells, but it alters the distribution of the glycosaminoglycan degradation products.

Authors:  S Tumova; B A Hatch; D J Law; K J Bame
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

Review 4.  Recent advances in the immunology of xenotransplantation.

Authors:  T Takahashi; S Saadi; J L Platt
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 5.  The endothelial glycocalyx as a barrier to leukocyte adhesion and its mediation by extracellular proteases.

Authors:  Herbert H Lipowsky
Journal:  Ann Biomed Eng       Date:  2011-10-08       Impact factor: 3.934

6.  Inhibition of inflammation induced shedding of the endothelial glycocalyx with low molecular weight heparin.

Authors:  Herbert H Lipowsky; Anne Lescanic
Journal:  Microvasc Res       Date:  2017-03-27       Impact factor: 3.514

7.  Blood management-issues: the panic of coagulopathic bleeding--is there a rational approach?

Authors:  Bruce D Spiess
Journal:  J Extra Corpor Technol       Date:  2011-03

8.  Protease Activity and the Role of the Endothelial Glycocalyx in Inflammation.

Authors:  Herbert H Lipowsky
Journal:  Drug Discov Today Dis Models       Date:  2011

9.  Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells.

Authors:  Dan Jane-Wit; Thomas D Manes; Tai Yi; Lingfeng Qin; Pamela Clark; Nancy C Kirkiles-Smith; Parwiz Abrahimi; Julie Devalliere; Gilbert Moeckel; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  Circulation       Date:  2013-09-17       Impact factor: 29.690

10.  Effects of TLR agonists on the hypoxia-regulated transcription factor HIF-1alpha and dendritic cell maturation under normoxic conditions.

Authors:  Rolf Spirig; Siamak Djafarzadeh; Tomas Regueira; Sidney G Shaw; Christophe von Garnier; Jukka Takala; Stephan M Jakob; Robert Rieben; Philipp M Lepper
Journal:  PLoS One       Date:  2010-06-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.